RxDoctor Payments Data

Keith Steinbecker, MD

Urology · Saint Louis, MONPI 1992763197

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 471 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations.

$9,510in general payments, 2019–2025

Across 471 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$1K
  • Myriad Genetic Laboratories, Inc.$633
  • Sumitomo Pharma America, Inc.$600
  • Boston Scientific$580
  • Procept Biorobotics Corporation$458
  • plus $5K from 54 others

What the payments were for

  • Travel & lodging$3584%
  • Food & beverage$9,06395%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)82$1,195
Astellas Pharma US Inc68$1,050
Myriad Genetic Laboratories, Inc.26$633
Sumitomo Pharma America, Inc.36$600
Boston Scientific18$580
Procept Biorobotics Corporation3$458
Johnson & Johnson(2 entities)16$304
Merck15$286
BD13$276
C. R. Bard, Inc. & Subsidiaries9$249
Rochester Medical Corporation10$240
Agiliti Health, Inc.6$234
Urogen Pharma, Inc.10$233
Ferring Pharmaceuticals Inc.8$203
Myovant Sciences Inc.10$191
Progenics Pharmaceuticals, Inc.7$161
Calyxo, Inc.8$156
Accord Healthcare, Inc.7$141
Pfizer8$137
Urovant Sciences Inc10$134
Tolmar Pharmaceuticals, Inc.8$132
Endo USA, Inc.5$119
Neotract Inc.5$116
Dendreon Pharmaceuticals LLC4$112
Antares Pharma, Inc.6$107
Axonics, Inc.5$103
Bayer5$98
SRS Medical Systems, Inc.1$93
Teleflex LLC6$92
Endo Pharmaceuticals Inc.6$83
Kerecis Limited1$75
Olympus America Inc.3$68
Blue Earth Diagnostics3$62
Acerus Pharmaceuticals Corporation3$55
Vertex3$54
ABC Home Medical Supply, Inc.3$52
Seagen Inc.3$47
EMD Serono, Inc.2$46
Clarus Therapeutics Inc.2$40
Koelis Inc.2$40
Civco Medical Instruments2$37
Novo Nordisk2$36
Tolmar, Inc.2$34
Zyla Life Sciences, Inc.2$28
Baxter Healthcare1$25
Convatec Inc.1$24
Travere Therapeutics, Inc.1$23
Photocure Inc1$23
Ambu Inc.1$22
Sanofi1$21
Aytu Biopharma, Inc.1$20
Lantheus Medical Imaging, Inc.1$18
AstraZeneca1$18
Angiodynamics, Inc.1$17
Laborie Medical Technologies Corp.1$17
E.r. Squibb & Sons, L.L.C.1$17
Palette Life Sciences, Inc.1$16
Mission Pharmacal Company1$16
Avadel Specialty Pharmaceuticals, LLC1$14
Profound Medical Corp.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,510 in reported general payments places this provider in the 80th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$184,071
Medicare patients
491
Services billed
3,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron353$203,654
GemtesaVibegron237$169,564
Mirabegron ErMirabegron15$6,658
Finasteride746$6,429
Tamsulosin Hcl764$6,027
Silodosin26$3,996
Methenamine Hippurate21$1,967
Cephalexin199$1,946
Potassium Citrate ErPotassium Citrate11$1,596
Solifenacin Succinate48$1,577
Oxybutynin Chloride ErOxybutynin Chloride117$1,487
Fosfomycin Tromethamine12$1,410
Testosterone Cypionate52$1,178
Testosterone19$969
Alfuzosin Hcl ErAlfuzosin Hcl54$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,050$203,654353 claims
Sumitomo Pharma America, Inc.Gemtesa$600$169,564237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 250 urology providers in Missouri.

Other urology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →